Bomb Report – Lifestyle
Author:
Telix Pharmaceuticals Limited
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
March 15, 2026
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
March 9, 2026
Investor Education Webinar
March 6, 2026
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
March 6, 2026
←
Previous Page
1
2